The first draft guidance newly released by ICH on “Drug Interaction Studies” is now available in DIDB Resource Center. Please note that you must be signed in to access.
The topic about Drug Interactions was endorsed by ICH Assembly in June 2018, and this draft is the first step towards a harmonized guidance.
This Guideline provides general recommendations on how to evaluate the DDI potential of an investigational drug. It is recognized that the DDI evaluation is generally tailored based on the specific drug, intended patient population, and therapeutic context. Alternative approaches can be used if they satisfy the requirements of the applicable statutes and regulations. The focus of the Guideline is the development of new drugs, but if new scientific information regarding the potential for DDIs is obtained after drug approval, additional DDI evaluation should be considered.